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Background: Patent foramen ovale (PFO) closure may reduce the frequency and severity of migraine headaches in patients who have significant 
right-to-left shunts and CT-scan or MRI evidence of silent brain lesions.
Aim and Methods:  We conducted a single-center, observational, prospective study to evaluate the impact of PFO closure on migraine attacks 
over time.
Between May 2000 and December 2008, 230 patients (mean age 48±14 years; 54% female) were consecutively treated for PFO closure with the 
same device type (Amplatzer PFO). All patients had significant right-to-left shunts, associated with moderate/severe migraine symptoms (n=49 
pts, 21%). Septal aneurysm was present in 9/49 (18%) patients. Among these migraineurs, 26 (53%) had previously experienced a brain transient 
ischemic attack with positive MRI documented brain transient ischemic attack. All patients were followed-up with transthoracic echocardiogram and 
clinical evaluation after 24 hours, three-, six-, twelve-months, and then yearly.
Results:  An acute and mostly disabling migraine attack occurred 24-48 hours after PFO device implantation in 20/49 (40.8%) patients. The 
global severity migraine score including intensity, duration, frequency and aura characteristics (according to Anzola’s classification) decreased from 
6.2±1.9 at baseline to 1.5±1.4 post PFO closure (p < 0.001).
A significant reduction in number (50%) and intensity (80%) of total attacks was observed in 22/49 (45%) patients at three-month follow-up. 
At twelve-month clinical visit, migraine disappeared in 8 (16%) patients, while in 26 (53%) migraine symptoms were furtherly reduced in their 
recurrency and disabling characteristics. These results were maintained at a mean follow-up of 36±24 months. Overall improvement in migraine was 
obtained in 69% of treated patients.
Conclusions:  This study showed a 21% incidence of migraine among patients with right-to-left shunt due to PFO and previous ischemic event. 
PFOs closure with the Amplatzer device in this population resulted in beneficial mid- and long-term reduction of migraine intensity and frequency in 
over 60% of patients.
